Information between 27th July 2024 - 5th October 2024
Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.
Select Committee Documents |
---|
Tuesday 3rd September 2024
Written Evidence - AstraZeneca ENB0044 - Engineering biology Engineering biology - Science and Technology Committee Found: Inflammatory Bowel Disease) and how such diseases influence drug absorption and delivery. |
Parliamentary Research |
---|
Reducing plastic waste - POST-PN-0724
Jul. 31 2024 Found: Science & Technology revealed that microplastics were 50% more prevalent in faeces of humans with inflammatory |
Non-Departmental Publications - Transparency |
---|
Jul. 30 2024
Commission on Human Medicines Source Page: Human Medicines Regulations 2012 Advisory Bodies Annual Report 2023 Document: (PDF) Transparency Found: University of Edinburgh Shahida Din GRID Additional British Society of Gastroenterolog y, Inflammatory |
Non-Departmental Publications - Statistics |
---|
Jul. 30 2024
Government Office for Science Source Page: Microbiome manipulation Document: (PDF) Statistics Found: There are ongoing clinical trials in the UK using FMT to treat liver disease, inflammatory bowel disease |
Arms Length Bodies Publications |
---|
Aug. 22 2024
NICE Source Page: Risankizumab for treating moderately to severely active ulcerative colitis Publication Type: Supporting evidence Document: Committee papers (PDF 4.64 MB) (webpage) Published Found: How to predict clinical relapse in inflammatory bowel disease patients. |
Aug. 08 2024
NICE Source Page: PillCam COLON 2 for investigation of the colon through direct visualisation Publication Type: Scope published Document: Final protocol PDF 362 KB (webpage) In development Found: family history, genetic conditions such as Familial Adenomatous Polyposis (FAP) and Lynch syndrome, inflammatory |
Jul. 30 2024
NICE Source Page: Maternal and child nutrition Publication Type: Draft guidance consultation Document: Evidence review: O PDF 9 MB (webpage) In consultation Found: requiring specific diets due to chronic diseases such as coeliac disease, food intolerances or allergies, inflammatory |
Jul. 30 2024
NICE Source Page: Guselkumab for previously treated moderately to severely active Crohn's disease ID6238 Publication Type: Invitation to participate Document: Final scope PDF 186 KB (webpage) In development Found: Inflammatory bowel disease (2015). NICE quality standard 81. |
Jul. 30 2024
NICE Source Page: Guselkumab for previously treated moderately to severely active Crohn's disease ID6238 Publication Type: Invitation to participate Document: Provisional stakeholder list (post-referral) PDF 169 KB (webpage) In development Found: Commentators (no right to submit or appeal) • NHS England Relevant research groups • Cochrane Inflammatory |
Jul. 30 2024
NICE Source Page: Guselkumab for previously treated moderately to severely active Crohn's disease ID6238 Publication Type: Invitation to participate Document: Equality impact assessment (scoping) PDF 129 KB (webpage) In development Found: Yes, the company noted during consultation that inflammatory bowel disease may be classed as a disability |
Jul. 30 2024
NICE Source Page: Guselkumab for previously treated moderately to severely active Crohn's disease ID6238 Publication Type: Invitation to participate Document: NICE's response to comments on the draft scope and provisional stakeholder list PDF 226 KB (webpage) In development Found: In line with recent appraisals in inflammatory bowel disease (TA888, TA905, TA925, TA956) and others |
Jul. 09 2024
NHS England Source Page: 2022/23 National Cost Collection Data Publication Document: The National Schedule of NHS Costs 2022/23 (Excel) Data and statistics Found: - Inflammatory Bowel Disease with Single Intervention, with CC Score 0-347794199.0720067348.580000002 |
Jun. 12 2024
NICE Source Page: Risankizumab for treating moderately to severely active ulcerative colitis Publication Type: Final draft guidance Document: Committee papers (PDF 4.63 MB) (webpage) Published Found: How to predict clinical relapse in inflammatory bowel disease patients. |
Sep. 05 2023
NICE Source Page: Risankizumab for treating moderately to severely active ulcerative colitis Publication Type: Invitation to participate Document: Final scope (PDF 197 KB) (webpage) Published Found: Background Ulcerative colitis is the most common inflammatory bowel disease. |
Jun. 07 2023
NICE Source Page: Risankizumab for treating moderately to severely active ulcerative colitis Publication Type: Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6209 Document: Draft scope post referral (PDF 210 KB) (webpage) Published Found: Background Ulcerative colitis is the most common inflammatory bowel disease. |
Scottish Cross Party Group Publications |
---|
Minute of Meeting for 18 September 2024
(PDF) Source Page: Cross-Party Group in the Scottish Parliament on Inflammatory Bowel Disease Published: 18th Sep 2024 Found: 1 Cross -Party Group on Inflammatory Bowel Disease (IBD) 18 September 2024, 6 -8pm Minute s |
Agenda for the Meeting on 18 September 2024
(PDF) Source Page: Cross-Party Group in the Scottish Parliament on Inflammatory Bowel Disease Published: 18th Sep 2024 Found: 1 Cross -Party Group on Inflammatory Bowel Disease Annual General Meeting Wednesday 18th September |
Minute of the Meeting on 13 December 2023
(PDF) Source Page: Cross-Party Group in the Scottish Parliament on Inflammatory Bowel Disease Published: 13th Dec 2023 Found: 1 Cross -Party Group on Inflammatory Bowel Disease 13th December 2023, 6pm Minute Present |
Registration Form 2024
(PDF) Source Page: Cross-Party Group in the Scottish Parliament on Inflammatory Bowel Disease Found: CROSS -PARTY GROUP REGISTRATION FORM NAME OF CROSS -PARTY GROUP Cross -Party Group on Inflammatory |
Annual Return 2023 to 2024
(PDF) Source Page: Cross-Party Group in the Scottish Parliament on Inflammatory Bowel Disease Found: Cross -Party Group Annual Return Name of Cross -Party Group Cross -Party Group on Inflammatory Bowel |
Scottish Government Publications |
---|
Friday 16th August 2024
Digital Health and Care Directorate Source Page: Records Management Code of Practice for Health and Social Care Document: Records Management Code of Practice for Health and Social Care v4.0 (PDF) Found: disease • Depression • Diabetes • Epilepsy • Heart Failure • Hepatitis • Hypertension • Inflammatory |